Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High Rates of PCSK9 Inhibitor Access & Initiation

J Clin Lipidol; ePub 2019 Jan 14; Reynolds, et al

An integrated specialty pharmacy service model in outpatient clinics produced high rates of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy access and initiation, a new study found. Researchers performed a single-center, cohort study of patients prescribed a PCSK9 inhibitor between September 2015 and December 2016 at Vanderbilt University Medical Center outpatient clinics. The primary end point was the percentage of PCSK9 inhibitor prescriptions resulting in access of the total prescriptions triaged to Vanderbilt Specialty Pharmacy. They found:

  • 299 patients met inclusion criteria (mean age 63 years, 46% female, 57% had commercial insurance, 70% had an atherosclerosis cardiovascular disease indication).
  • 96% of prescriptions resulted in access to a PCSK9 inhibitor.
  • Most patients wee approved with an initial prior authorization.
  • The median time to approval was 8 days.
  • 53% of patients approved for therapy received financial assistance and 94% initiated therapy.


Reynolds VW, Chinn ME, Jolly JA, et al. Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates. [Published online ahead of print January 14, 2019]. J Clin Lipidol. doi:10.1016/j.jacl.2019.01.003.